Note: Descriptions are shown in the official language in which they were submitted.
765~
BACKGROUND OF THE INVENTION:
This invention relates to new routes for the
synthesis of 3',4'-dideoxykanamycin B which is anti-
bacterial against a variety of gram-positive and gram-
negative bacteria and particularly effective in inhibiting
kanamycin-resistant organisms such as kanamycin-resistant
Staphylococci and kanamycin-resistant Escherichia coli.
DESCRIPTION OF THE PRIOR ART:
3'g4'-Dideoxykanamycln B having the structure:
.~ .
5 ~ ~ ~H2
. 4' ~ ~ 1 o ~ l
NH2
:~ . 6"
, HOCH2 j
4" ~ O~
,` H~éV
:
- .
` 10
has hitherto been prepared by a method comprising pro-
:. tecting~the five amino groups and all or a part of the
hydroxyl groups other than 3'- and 4'-hydroxyl groups -
of kanamycin B by a conventional method, sulfonylating
the 3'- and 4'-hydroxyl groups to afford a deri~ative
having 3'- and 4'-disulfonic ester groups~ removing the ::
.: 31_ and 4'-disulfonic ester groups by known methods to
: give a 3',4'-unsaturated compound, reducing the 3'~4'-
. 2
','- ~ ~
. . :
:
.~ 6~
unsaturated compound and removing the residual protecting
groups. The known method requires nine steps from kana-
mycin B to 3',4' dideoxykanamycin B (see British Patent
Specification No. 1,349,302). Further, the method re-
quires the use of sodium iodide and zinc powder in large
amounts in the step for removing the 3' and 4'-disulfonic
ester groups, thus involving questions of iodine resources
and of environmental pollution resulting from disposal
of by-products. Therefore, the development of new, more
advantageous method for synthesis of 3',4'-dideoxykanamycin
B has eagerly been desired from the industrial point o~
view.
i SUMMARY OF THE INVENTION:
It is the primary object of this invention to pro-
vide some new routes for the synthetic preparation of 3',
4'-dideoxykanamycin B which are advantageous over the
`I prior art in that thèy do not use an alkali metal bromide
¦ or iodide and zinc powder, but use other reagents o~ less
expenses. All the new processes originate from kanamycin
B as in the prior art but pass through a new route of
reaction.
According to a first aspect of this inventiona
therefore, there is provided a process for the preparation
of 3',4'-dideoxykanamycin B or its acid ad~ition salts and
mt~dia~es t~hereof o~rising one or mDre of the ~olla~ng steps:
(1) treating with a xanthate a 3',4'-epoxy derivative of
an amino- and hydroxyl-protected kanamycin B of the formula:
,
~65~6
.
CH2~HCOOR NHCOOR
~ ~ HCOOR
o-~l ~f
~HCOOR
OCH2¦ O (I)
Z/~l
wherein ~ represents a hydrogen atom or an alkyl or aryl
group, Z represents an alkylidene,~arylidene~ cyclohexyli-
dene or tetrahydropyranylidene group and the: 3',4'-epoxy
. group is in ~- or ~-position whereby to form a 3',4'-
: ~dideoxy-3'-eno-1canamycln B derivatlve o~ the formula:
~ ~ CH2~HCOORI ~COOR
L ~
~HCOOR
OCH2 O
Z~
~ '
' ' ,.
' ~ ., ' " ~ '' , ~ '' .'
. , : ' ~ ' ', ~
~7~5~6
wherein R and Z have the same meaning as defined above
together with a 3',4'-episulfido-kanamycin B derivative
of the formula:
CH2 i~HCOOR NHCOOR
~- ~
NHcoox ~ /
OCH2 0
/~ (III)
OH
,
i~ wherein R and Z have the same meaning as defined above
and the 3',4'-episulfide group is in ~- or ~-position;
(2~j isolating the 3'~4'-dldeoxy--3'-eno-kanamycin:B
:~ derivative from the reaction mixture;
, . .
. (3) removing the amino-protecting groups -COOR and
hydroxyl-protecting group Z of the 3',4'-dideoxy-3' eno
derivative thus isolated in a conventional manner to
. form 3',4'-dideoxy-3'-eno-kanamycin B of the formula:
,; .
,, ' ~'.
~ .
.,~
~L~7~:i5~6
CH2NH2 ~H2
N~z
NH2
XOC~2
~ O (IV)
~0~
HO ~
o~ .
and (4) hydrogenating the compound thus formed in a
conventional manner to form 3i,4'-dideoxykanamycin B,
and, if desired, converting the compound thus ~ormed
into an acid addition salt thereof.
The step (1) of the first aspect process of this
invention, that is the treatment of a 3',4'-epoxy deriv-
ative of the formula (I) in either a- or ~-form with a
xanthate, may be effected in an organic solvent, pref~
erably at a temperature of 50~100C. The organic
solvent may preferably be a lower alkanol such as methanol
and ethanol. The xanthate to be used for this treatment
may be those of the formula R'OCSSMe where R' is a lower
alkyl group, Me is an alkali metal such as sodium or
potassium. Generally, this reaction gives a 3',4'-
dideoxy-3'-eno derivative of the formula (II) as a first
product in admixture with a 3',4'-episulfide derivative
of the formula (III) as a second product after washing
.
,. .: . : , . . , . ~
" ' ~ ' ~ . ' ' .,,
7~S66
the reaction mixture with water, recovering the solvent
by distillation and concentrating the residue to dryness.
The mechanism of reaction between the 3',4'-epoxy
derivative of the formula (I) and the xanthate has not
yet been made clear, but a presumable possibility is that
the conversion of 3',4'-epoxy derivative into correspond-
ing 3',41-dideoxy-3'-eno derivative of the formula (II)
proceeds via corresponding 3',4'-episulfide derivative
of the formula (III).
; 10 The isolation of the first and second products of
the step (1) from each other, i.e. the step (2) of the
first aspect process, may be effected, preferably by
chromatography, for example silica-gel thin layer chromato-
; graphy in a usual manner, for example using a mixture
~ (e.g. 1:1 by ~olume) of carbon tetrachloride and acetone
.,; .
as developer.
The step (3) of the first aspect process of this -
invention for the removal of the amino-protecting groups
-COOR and hydroxyl-protecting group Z may be carried out
in a usual manner. For example, the removal of the
hydroxyl protecting group Z may first be effected by a
mild hydrolysis with a dilute hydrochloric acid or an
aqueous acetic acid and then the amino_protecting groups
may be removed by a hydrolysis with barium hydroxide or
by hydrogenolysis in the presence of a palladium catalyst.
The step (4) of the first aspect process, that is the
hydrogenation step, may be carried out in a known manner.
Thus, a catalytic reduction with hydrogen in the presence
of a known hydrogenation catalyst comprising a platinum
group metal such as platinum or palladium may preferably
,;
'' '
~6
be applicable to the step (4). Raney nickel catalyst
may also be used for this purpose.
The first aspect process of this invention is
advantageous over the prior ar~ process above-mentioned
in that
the formation of 3',4'-unsaturation can be
achieved without relying on the reaction involving
the use o~ an alkali bromide or iodide and zinc
powder;
~ as the final intermediate compound which is to
be converted to the desired product, 3',4'-
dideoxykanamycin B, in the last step, 3',4'-
dideoxy-3'-eno-kanamycin B, i.e. the compound
of the formula (IV) free from any protecting
group can be obtained;
- in the last step, the catalytic hydrogenation
can be achieved relatively easily with much less
impurities derived from reagents used, so that
the purification of the final product is required
only to a less extent than in the prior art
process wherein the step for removin~ amino- and
hydroxyl-protecting groups is carried~fout after
the step for the hydrogenation.
It will be appreciated, however, that the order of
the steps (3) and (4) of the first aspect process of this
invention can be reversed, if desired, to follow the known
order adopted by the prior art process.
The final product, 3',4'-dideoxykanamycin B in free
-~ base form, may be converted, if desired, to an acid addition
salt derived from an inorganic or organic acid. For example,
,
5~
sulfate of 3',4'-dideoxykanamycin B may be obtained by
adding dilute sulfuric acid to an aqueous solution of the
free base to adjust the pH value to 6.8, treating the
solution with decoloring carbong filtering the solution
and freeze-drying the filtrate.
We have further found that the 3',4'-episulfide
derivative of the formula (III) which is formed as second
product in the step (l) of the first aspect process of
this invention is also useful as intermediate for the
j 10 preparation o~ 3',4'~dideoxykanamycin B. Our discovery
in this respect is that there are two routes for converting
the 3',4'-episulfide derivative of the formula (III) to
a known useful intermediate for the preparation of 3'g
4'-dideoxykanamycin B; the first route is to treat the
3',4'-episulfide derivative with an acid to form 3',4'-
dideoxy-3'-eno-kanamycin B of the formula (I~) and the
second route ls to treat the 3',4'-episulfide derivative
with hydrazine or Raney nickeI to form a 3',4'-dideoxy-
3'-eno-kanamycin B derivative of the formula ~II).
According to a second aspect process of this
; ~ invention, therefore, we provide a process for the prepara-
tion of 3',4'-dideoxykanamycin B or its acid addition saltsand
inb~diates thereof o~rising one or more of the foll~ steps;
(1) treating with a xanthate a 3',4'-epoxy derivative of
an amlno- and hydroxyl-protected kanamycin B Or the lormula:
,
,
7~66
CH2~XCOOR ¦ NHCOOR
HCOOR
~0~ ~
~HCOOR
OCH2 O (I) :
Z/~/ ~ ~
,'~ ' .
~: '
~ ' :
wherein R represents a hydrogen atom or an alkyl or aryl
group, Z represents an alkylidene, arylidene~ cyclohexylidene
or tetrahydropyranylidene group and the 3',4'-epoxy group
is in ~- or~ ~-position whereby to form a 3',4'-ep:isul~ido~
kanamycin B derivative of the formula~
, . .
.
NHCOOR
XCOOR ~;
' S~ O ~ ` ~
j NHCOOR
/. ~ ., :
/
~ (III)
." \o~ `
` OH
: - .
,. .
-- 10
. .
'
:' , :. ' :.
5~
wherein R and Z have the same meaning as defined above
and the 3'34'-episulfide group is in ~- or ~-position
together with a 3',4'-dideoxy-3'-eno-kanamycin B derivative
of the formula.
' .
~2NHCOOR ¦ NHCOOR
~ NHCOOR
'~ O ~
NHCOOR
OC~ O (II)
z\/i~
OH
.
wherein R and Z have the same meaning as defined abovej
(2) isolating the 3',4'-episulfido-kanamycin B derivative
from the reaction mixture;
(3) treating the 3~,4'-episulfide derivative thus isolated
with an acid t.o form 3',4'-dideoxy-3'-eno-kanamycin B of
the formula:
-- 11 --
~ ~7~5~i6
.
C~I2N~I2 ~2
NIIZ
H 2
HOCH2 o ( IV )
'~ ,/~ 0 / :
¦~: N~32 ~V
HO \~/
` ~ : OH
.
.' .
and (4) hydrogenating the compound thus formed in a
conventional manner to form 3',4'~dideoxykanamycin B;
and, if desired, converting the compound thus~formed into
an acid additlon salt thereof.
The steps (1)~,(2) and (4) of the second~aspect
process o~ this invention correspond to the steps (l),
(2) and (4) of~the first aspect process as above-mentioned~?
respectively. ~ ~ -
:
The step (3~ of the second aspect process~ i.e. the
treatment of the 3',4'-eplsulfide der1vative of the formula :
(III) with an acid may preferably be carried out i~ a lower ~
. .
alkanol such as methanol and ethanol using a hydrohalogenic
acid such as concentrated hydrochloric acid and hydrobromic
acid. In general ? however ? a non-oxidizing mineral acid,
for example sulfurlc acid, may be used for this treatment.
Preferably, the treatment may be carried out at a tempera-
ture of 0~30C.
.'
- 12 - ~
;
.:
.. . . . . .
. , . , , ' , . ' .
. . ' . '.
~7~
According to a third aspect process of this inven-
tion, there is provided a process for the preparation of
3',4'-dideoxykanamycin B or its acid addition salts and
int~E~a*es thereof ~x~rismg one or more of the foll~ng steps:
(1) treating with a xanthate a 3',4' epoxy derivative of
an amino- and hydroxyl-protected kanamycin B of the formula:
;
CH2l~XCOOR ¦ NHCOOR
~0 ~NHCOOR
~ ~\~
~ICOOR
OC~I2 o (I)
Z~
. , .
OH.
wherein R represents a hydrogen atom or an alkyl or aryl
group and Z represents an alkylidene; arylidene, cyclo-
hexylidene or tetrahydropyranylidene group whereby to form
a 3'g4'-episulfido-kanamycin B.derivative of:the fo~mula:
- 13
~ 65~6
CB2~HCOOR I~HCOOR
Coo~ ~
NHCOOR
OCH2 ( III ) . .
Z/~ \l / :
HCOOR /V
` 'H'
OH
. ~
wherein R and Z have the same meaning as defined above
and 3 t, 4'-episulfide group is in a- or ~-position together
: with a 3',4'-dideoxy-3'-eno-kanamycin ~ derivative of the
formula: :
:: :
CH2NHCOOR j ~IHCOOR
o~
NHCOOR
( II )
z/l/~
OH
- 14 -
.
.. : .
~765i~
wherein R and Z have the same meaning as defined above;
(2) treating the reaction mixture from the step (1) with
hydrazine or Raney nickel to convert the 3',4'-episulfide
derivative of the formula (III) into a further amount of
the 3',4'-dideoxy-3'-eno-kanamycin B derivative of the
formula (II) above;
(3) removin~ the amino-protecting groups -COOR and hydroxyl-
; protecting group Z of the 3',4'-dideoxy-3'-eno derivative
thus formed in a conventional manner to form 3',4'-dideoxy-
3'-eno-kanamycin B of the formula:
'
CH2NH2 NH2
~u\
NH2
; / (IV~
HOCH2 o/
,'`,' ' '~ ~/
' '
HO ~
OH
'
and (4) hydrogenating the compound thus formed in a con-
ventional manner to form 3',4'-dideoxykanamycin B; and,
if desired, converting the compound thus formed into an
acid addition salt thereof.
The steps (1),(3) and (4) of the third aspect process
of this invention correspond to the steps (1),(3) and (4)
of the first aspect process as above-mentioned, respectively.
- - 15
65~ii6
In the step (2) of the third aspect process, the
treatment with hydrazine may preferably be effected in
a lower alkanol such as methanol and ethanol using hydrazine,
particularly in the form of hydrate NH2NH2-H20~ at room
temperatures, usually 15~-25C. The amount of hydrazine
to be used may preferably be about 10~30 moles per mole of
the compound of the formula (III). The treatment with
Raney nickel, if adopted for the step (2), may preferably .~
be carried out by dissolving the compound of the formula -
(III) in a lower alkanol, for example methanol, adding
Raney nickel to:the:solution in an appropriate amount, for .example threefold amount in respect of the amount of the
compound of the formula (III) on the weight basis and
maintaining the mixture under stirring at room temperatures, ~:
usually 15-25C for 1-3 hours
In the third aspect process of this invention, the
step (2) is also applicable,.if desired, to the 3',4'-
episulfide derivative of the formula (III) which has been
isolated from the 3',4'-dideoxy-3'-eno derivative o:f the
formula (II), but: it is usually advantageous to apply the
step (2) directly to the reaction mixture from the step (l)
containing both the compounds of the formulae (II) and (III)
particularly in large scale operations.
We have further found that the 3 t, 4 9 -dideoxy-3'-
eno derivatives of the formula (IV) can be produced from
the 3',4'-epoxy derivatives of the formula (I) through
another route involving four steps with a high overall
yield. This route comprises the steps of
(l) treating a 3',4'-epoxy derivative of the formula:
16
~765~i
CH2NHCOOR NHCOOR
NHCOOR
0~ --~ ` ' .
NHCOOR
OCH2 O (I)
Z\/~/
OH
wherein R and Z have the same meaning as de~ined above
with an acylating~agent, for example benzoyl chloride, in
a conventional manner to acylate the 2"-hydroxyl group,
giving a compound of the formula:
,
CH2NHCOOR
~HCOOR
NaCOOR
`f \ ~ ~o. ~ OH
~ ~
NHCOOR
(V)
~ OCH2 O
Z\o 1~V
' ' OY
~76566
wherein R and Z have the same meaning as defined above and
Y represents an acyl group;
(2) treating the compound of the formula (V) thus obtained
with an alkali or alkaline earth metal iodide, for example
sodium iodide, preferably in the presence of sodium acetate
and glacial acetic acid, to give a compound of the formula:
:
.
~HCOOR ¦ NHCOOR
~ O ~ ~HCOOR
I ~ ~
NHCOOR
,
OCH2 0 (VI)
~ Z\/o~
Y
~. .
where R, Z and Y have the same meaning as defined above;
: (3) subjecting the compound of the formula (VI) thus
obtained to 3'-O~sulfonylation with a sulfonylating agent
such as mesyl chloride, tosyl chloride and benzylsulfonyl
chloride in a known manner, preferably in pyridine at a
temperature below 10C, to form the compound of the formula:
: `
.` , .
- 18 - ~
, '
7 Ei56~
CH2 l!lHCOOR
NHCOOR
I~ C~ ~
NHCOOR
OCH2 / (VII
Z~
OY
;: :
.,
where R, Z and Y have the same meaning as defined above
and W represents mesyl, tosyl or benzylsulfonyl group,
: (4:) heating the reaction mixture from the step (3) above~,
::
preferably to a temperature of 80 100C to convert the
compound of the formula (VII) into the compound o~ the
: ~ormula~
C~I2 ~HCOOR I NHCOOR
, . L~o ~
~ ~ o
NHCOOR
'' ' /
.
OCH 2 O
( VIII )
\ o\ N~OGR/V
OY
-- 19
~7~56~
wherein R, Z and Y nave the same meaning as defined above;
and (5) treating the compound of the formula (VIII) thus
obtained with an alkali or alkaline earth metal alcoholate,
for example sodium methoxide, in a known manner to give
~ 3',4'-dideoxy-3'-eno derivative of the formula (II) above.
; The compound, penta-amino~protected, 4",6"-hydroxyl-
protected~ 3',4'-~-epoxy derivative of kanamycin B re-
presented by the formula:
~ , .
., .
~ CH~2NHCOOR ¦ ~HCOOR
~_ 0 ~
~HCOOR
/ (IX)
' OCH2 0
' ' Z/~O~ ' - '
\ o~HCOOR~
~ .
~ OH
, . .
,
`~ 10 wherein R and Z have the same meaning as defined above
which is to be used as starting compound of the first to
third aspect processes according to this invention is a :
: new compound and constitutes another aspect of this
invention.
-~. The new 3',4'-~-epoxy derivative of kanamycin B
of the formula (IX) can be derived from kanamycin B through
several reaction steps as explained below. .
First of all, kanamycin B is subjected to amino-
_ 20
s~
protecting step in a known manner. Thus, kanamycin B is
reacted with a chloroformate of the formula RCOOCl wherein
R represents a hydrogen atom or an alkyl or aryl group
such as phenyl to protect all the five amino groups of
kanamycin B in the form of urethane group -NHCOOR in the
same manner as that described in Japanese Patent Publica-
tion No.7595/75, affording penta N-protected kanamycin B
of the formula:
CE[2NHCOOR ~
~HCOOR
HCOOR
l~HCOOR
(X)
HOCH2 ,O
: ~0~
~ HO\~
:
.
wherein R has the same meaning as defined above.
The next step is 4",6"-hydroxyl-protecting step
which is also carried out in a known manner. Thus, the
compound of the formula (X) may be reacted with a known
hydroxyl-protecting agent selected from an a].kylidenating
agent, an arylidenating agent, a cyclohexylidenating agent
and a tetrahydropyranylidenating agent. Typical examples
of such hydroxyl-protecting agent include acetaldehyde,
2',2'-dimethoxypropane, anisaldehyde, benzaldehyde, dimethyl-
- 21
~765~
acetal, tolualdehyde, l,l-dimethoxycyclohexane and l,l-
dimethoxytetrahydropyran. The reaction may preferably be
carried out in a polar organic solvent, e.g. dimethyl-
formamide in the presence of a catalytic amount of p-
toluene sulfonic acid at room temperatures, for example
15~25C for 15~20 hours. This brings the selective in-
troduction of the hydroxyl-protecting group in 4",6"-
positions, thus yielding 4't,6"-O-protected derivative of
the formula: -
,' '
CH2~HCOOR
NHCOOR
~t
¦/ \t t/ \~HCOOR ,~
HO~ O~
NHCOOR
`~ (XI)
OCH 2 O
Z~
' '' "
wherein R has the same meaning as defined above and Z
represents an alkylidene, arylidene, cyclohexylidene or
tetrahydropyranylidene ~roup. In this selective reaction,
it is desired that the temperature should be kept not to
exceed 30C because there may also occur the attack of the
hydroxyl~protecting agent on the 3'- and 4'-hydroxyl groups
at higher temperatures.
~he compound of the formula (XI) is then subjected
- 22
~7~
to acylation reaction for the purpose of selective protec-
tion of the 2"- and 3'-hydroxyl groups with hydroxyl-
protecting group of an acyl type. The acylation step may
usually be carried out by dissolving the compound of the
formula (XI) in pyridine, adding an acylating agent such
as an acyl chloride under a low temperature condition,
preferably below 5C and maintain.ing the mixture under
stirring for several hours.
Preferred acylating agent may be an acid chloride
of an alkanoic acid having 2~4 carbon atoms such as acetyl
chloride or an aroyl chloride such as benzoyl chloride.
The use of benzoyl chloride is most preferred. The use
of a temperature below 5~C for the acylation step does
not affect the 4~- and 5-hydroxyl groups which are relative-
; ly low in reactivity. Thus, 2",31-diacyl derivative of the
formula:
CH2~HCOOR~ NHCOOR
~0 1 .
NHCOOR
H~ ~ O \~
NHCOOR
/ (XII)
- OCH2 O
Z~
OY
wherein R and Z have the same meaning as defined above,
- 23
and X and Y each represent an acyl group, for example
an alkanoyl, particularly a lower alkanoyl such as acetyl
or an aroyl such as benzoyl may be produced.
In the acylation step, 2"-monoacylated derivative,
i.e. a compound of the formula (XII), but wherein X re-
presents a hydrogen atom may be obtained, if desired for
some purposes, by conducting the acylation reaction under
a milder conditions. Thus, in case of benzoyl chloride
being used as acylating agent, a major proportion of 2t'-
monobenzoyl derivative may be obtained under such condi-
tions that benzoyl chloride is added at a temperature
below 0C slowly and in small parts. On the other hand,
at least a ma~or proportion of 2",3'-dibenzoyl derivative
may be obtained when benzoyl chloride is added at a time
at a temperature between 0C and room temperatures, pref-
erably 0C and 5C. If 2"-monoacyl and 2",3'-diacyl
deri~atives are obtained in the form of a mixture, the
isolation of the respective derivatives may be effected
by a chromatographic separation technique in a known
manner, per se, for example by silica-gel thin-layer
chromatography using 2:1 by volume of chloroform-methanol
as developer.
The compound of the formula (XII) is then subjected
to 4'-0-sulfonylation to form 4'-0-sulfonylated derivative
of the formula:
- 24
'
~6S~
CX2NHCOOR
NHCOOR
UO~ ~Y I
N~COOR
(XIII )
O~H2
Z\/o ~
~
wherein R, Z, X and Y have the same meaning aB defined
above and W represents mesyl, tosyl or benzylsulfonyl
group. This step may preferably be carried out by re-
acting the compound of the formu:la (XII) with~mesyl chlo-
ride, tosyl chloride-or benzylsu:Lfonyl chlorlde in pyridine.
The 4'-0-sulfonylation may be~conducked at a temperature
of up to 50C. The most pre~erred sulfonylating agent is
mesyl chloride.
:
The 4'-0-sulfonylated derivative of the formula
(XIII) thus obtained~is then converted to 31,4'-~-epoxy
derivative of the formula (IX) above-mentioned as main
product by treating it with a metal alcoholate. The
epoxidation reaction may preferably be carried out by
dissolving the compound of the formula (XIII) in a solvent,
for example water, a lower alkanol such as methanol or
ethanol, diglyme, sulforane, tetrahydrofuran or dimethyl-
sulfoxide, adding to the solution a metal alcoholate,
: : :
~ 25 _
:' ~ .
' '~ ' ' ' ' ':
: . :
- ~7~
usually an alkali or alkaline earth metal alcoholate such
as sodium, potassium, or lithium alcoholate, particularly
a lower alkoxide, for example sodium methoxide or sodium
ethoxide and maintaining the mixture at room temperatures,
usually 15~25C, suitably for 1~3 hours. During the
epoxidation reaction, the hydroxyl-protecting group Y in
the 2"-position is removed because of alkaline condition,
thus the ~ree 2"-OH group is regenerated in the 3',4'-~-
epoxidized derivative o~ the formula (IX).
3',4'-a-Epoxy derivative corresponding to the 3',
4'-~-epoxy derivative of the formula (IX) may be derived
from 3t-O-tosyl derlvative corresponding to the 4'~O-
sulfonylated derivative of the formula (XIII) above, i.e.
the compound of the formula (XIII), but whereln W is
hydrogen and X is tosyl group in the same manner as that
of the 3',4'-epoxidation step as above-mentioned, i.e.
by treating with an alkali-metal alcoholate such as sodium
methoxide, details~of which is given in DT OS No.2,555,479.
A diagramatic reaction scheme is given below to
;~ 20 show the preparation of 3',4'-dideoxykanamycin B starting
from kanamyoln B via a new intermediate, 3',4'-~-epoxy
derivative of the formula (IX), which is treated according
to the processes :f this lnvention.
:
.
- 26
. ' ~
~76~,6~
Kanamycin B
¦ Protection of five NH2 groups
~ with -COOR group
CH2NHCOOR NHCOOR
COO:~
~HCOOR
' . / :
.-~ O
:0c~2 'I
COOR
HO
¦ Protection of 4"- and 6
OH groups with group Z
CX2NHCOOR ¦NHCOOR
, ~ 0 ~ ~ ~HCOOR
~/~
~ NHCOOR
: O ':' ,
/,~0'
\ ~ NHCOOR ~ ~
- 'H '
OH
, :
- ~
.
5~
Protection of 2"- and 3'-
OH groups with acyl groups
. ~ Y and X, respectively
; CH2NHCOOR ~HCOOR
. ~0 ~ '~.''` '
NHCOOR
HO
o o
~: Z\~/ ' ~'.'
¦ 4'-O-Sulfonylation
~ l (Introduction of:W group)
: CH2NHCOOR NHCOOR
~ ~ ~ COOR ~ ~ -
. WO~ O--~
COOR OCH2
, / .,1--
HCOOR
' ~ \~/ '
oy
. 3',4'-Epoxidation with
.~, , ,
i ~ an: alcoholate
,
CH2~XCOOR ~IHCOOR
o ,~ :
HCOOR
," ~--\f~/~ '. :,
1~ NHCOOR
~ C~2
/ ~O O
'
- 28
.
'
~ 71~6~
Treatment with a xanthate
(Route A)(Route B)(Route C)
1- ._
~CF~HCOOR ~,R ~HCOOR ~HCOOR
ICOOR / ~ HCOOR
~ ~ ~ (~-0~
NHCOOR / ~COOR
OCHz OCH2
Z/ ~/ Z~
OH
Treatment with
. hydrazine or Raney nickel
(Route C)
~ .
Treatment
Hydrogenation Removal of the NH2-and OH-protections with an acid
(Route D) (Route A)(Route C) 1 (Route B)
,~ ~ ~ 1, ,
CH2NHCOOR ~COOR ~2~H2 I~H2
~_ o ~COO~ 6~ o ~ ~ ;
NHCOOR / NH2
/
O O
OCH2 / HOCH2
Z~o~! ~~'
. OH OH
:
_ ~9 -
- ~
~L~3)76566
\ Removal of the
\ NH 2- and OH-protections /Hydrogenation
\(Route D) ¦ (RouteA)(Route B)(Route C)
; ' ~U `l ,,
CH2~2 NH2
~ ~ ~
. l!lH2 `
. ~ /
O
HOCH2
. ~ O
` ~NH
~ \I V
OH
Route A = The first aspect process of this invention
Route B = The second aspect process of this invention
Route C = The third aspect process of this invention:
Route D = An alternative of the first or third aspect
process of tbis iLven~ion
'` ~
.
- 30
. .
.' '' ' `- ~. '
.:
PREFERRED EMBODIMENTS OF THE INVENTION:
This invention is further illustrated by way of
Examples which include overall steps starting from
kanamycin B and leading to the final product, 3'g4'-
dideoxykanamycin B, through several routes according
to khis invention.
Example 1
(1) Preparation of penta-N-ethoxycarbonylkanamycin B
Penta-N-ethoxycarbonylkanamycin B was prepared
from kanamycin B free base by the method described in
Example 1 of British Patent No.1,349,302.
(2) Preparation of 2",3'-di-0-benzoyl-penta-N-
ethoxycarbonyl-4",6"-0-cyclohexylidene-kanamycin B
Penta-N-ethoxycarbonylkanamycin B (10 g) was
suspended in dimethylformamide (70~1 ), to which
was added p-toluene sulfonic acid until the pH of ~ `
: the suspension was lowered below 3.0 and then added
cyclohexanedimethylketal (10 ml). The mixture was
maintained at 25C under stirring for 18 hours. The
completion o~ the reaction was con~irmed by thin layer
.
chromatography using silica gel (made by Merck) as ~:
stationary phase and chloroform-methanol (10:1 by
volume) as developer and the resulting reaction mix~
ture was neutralized with triethylamine. The neu~
tralized liquid was concentrated under vacuum to
obtain a residual liquid of 25 ml which was then dis-
solved in pyridine (150 ml). After cooling the
solution to a temperature of 0~5C, benzoyl chloride
(3.9 ml) was added thereto and the mixture was kept to
cause reaction for 3 hours. The completion of reaction
- 31
~t~7~5t~
was confirmed by thln layer chromatography. Water
(5 ml~ was added to the resulting mixture and the
mixture was stirred at room temperature for 30
minutes, concentrated and poured into wa~er (200 ml)
to form preclpitate which was recovered by ~iltration.
Yield 12.7 g (95%). After the purification by a
conventional siiica-gel chromatography, the titled
compound had the following physical properties:
~]D ~ 76.6 (c=17~ pyridine); mp. 233~235C.
Elementary analysis:
Found: C 55.98; H 6.44; N 5.60%
Calculated for Cs3H73Ns22:
C 56.22; H 6.51; N 6.19%
(3) Preparation of 2",3'-di-O-benzoyl-penta-N-
; ethoxycarbonyl-4",6"-0-cyclohexylidene-4'-O-mesyl-
kanamycin B
2",3'-dl-O-benzoyl-penta-N-ethoxycarbonyl-4",
6"-0-cyclohexylidene-kanamycin B (5g) was dissolved
in pyridine (100 ml3, to which was added mesyl chloride
(1.4 ml) and the mixture was maintained at 40C under
:
~stirring ~or 1.5 hours. After the mix~ure was cooled
to room temperature, water (5~ml) was added to the
mixture to decompose~the excess mesyl chloride and
the mixture was concentrated. To the concentrate was
.
added water (200 ml) to precipitate the titled compound,
which was recovered by filtration. Yield 5.0g t94%);
~a]~ 103.6 (c=l.0, pyridine); mp. 176~179C.
Elementary analysis:
Found: C 53.28; H 6.25; N 5.41; S 2.95%
~ 30 Calculated for Cs 4 H 75 Ns 24S:
:'
~76~66
C 53.59; H 6.25; N 5.79, S 2.65%
(4) Preparation of 3',4'-~-epoxy-penta-N-ethoxy-
carbonyl-4",6"-0-cyclohexylidene-kanamycin B
2"~,3'-Di-0-benzoyl-penta-N-ethoxycarbonyl-
4",6"-0-cyclohexylidene~4'-mesyl-kanamycin B (5 g)
was dissolved in methanol (100 ml), to which was
added sodium methylate (2.2 g). The mixture was
maintained at room temperature under stirring for
2 hours. After the completion of reaction was con-
f~rmed by thin layer chromatography using silica gel
as stationary phase and carbon tetrachloride-aceto~e
tl:l by volume) as developer, the reaction mixture
was ice-cooled, neutralized with concentrated hydro-
chloric acid (1.25 mlj and concentrated. To the
neutralized concentrate was added water (100 ml) to
precipitate the titled compound which was recovered by
filtration. Yield 3.5 g (95%); ~]D + 37.8 (c=l.0,
pyridine), mp. 254~258C (decomposition with foaming).
Elementary analysis:
.
;~ 20 Found: C 51.86; H 6.89; N 7.58; 0 33.67%
- Calculated for C 3 g H~3NsOls:
.
C 51.69, H 7.02; N 7.73; 0 33.55%
(5) Preparation of 3',4'-dideoxy-3'-eno-penta-N-
etboxycarbonyl~4"~,6"-0-cyclohexylidene-kanamyGin B
3',4'-~-Epoxy~penta-N-ethoxycarbonyl-4",6"-0-
cyclohexylidene-kanamycin B (80o mg) was suspended
in n-butanol (40 ml), to which was then added potassium
n-butylxanthate (1.7 g) and the reaction was conducted
at 80C for 4 hours. After the completion of reaction
was confirmed by silica-gel thin layer chromatography
.
~ - 33
~L~7~
using carbon tetrachloride-acetone (1:1 by volume)
as developer, the mixture was cooled and washed with
water (4G ml x 2) and the resulting butanol layer
was concentrated to dryness. Yield 900 mg. This was
confirmed by silica-gel thin layer chromatography to
be a mixture of 3',4l-dideoxy-3'-eno-penta-N~ethoxy-
- carbonyl-4 1l, 6"-cyclohexylidene-kanamycin B and 3l,4t_
; episulfido-penta-N-ethoxycarbonyl-4",6"-O-cyclohexyli-
dene-kanamycin B in approximately 1:1 proportion.
The mixture was subjected to silica-gel thin
layer chromatography using carbon tetrachloride-acetone
; (5:1 by volume) as developer, affording 3',4'-dideoxy-
3'-eno-penta-N-ethoxycarbonyl-4",6"-cyclohexylidene-
kanamycin B with [a32D f + 24.7 (c=l.0, methanol) and
3',4'-episulfido-penta-N-ethoxycarbonyi-4",6"-O-cyclo-
2s
hexylidene-kanamycin B with []D of ~ 10.8 (c~=l.0,
H20j and melting point of 250-260C (with decomposi-
tion), separately.
Elementary analysis of the latter compound:
Found: C 50.41; H 6~.95, N~7.45; S 3.48%
Calculated for C39H63NsO~sS:
~ C 50.79; H 6.90; N 7.60; S 3.48%
(6) Preparation of 3l,4l-dideoxy-3'-eno-kanamycin B
3'~4'-Dideoxy-3l-eno-penta-N-ethoxycarbonyl-
4l',6"-0-cyclohexylidene kanamycin B (475 mg) was
dissolved in methanol (5 ml), to which was added an
amount of 1 N HCl sufficient to adjust the pH value
of the solution to 2Ø The solution was heated at
50C for 30 minutes and, after adding water (5 ml)
and then barium hydroxide octahydrate (1.4 g)~ further
- 34
~L~765~6
heated to distill off the methanol and the remaining
mixture was refluxed for 8 hours and then cooled.
Carbon dioxide gas was passed through the
cooled mixture and barium carbonate thus formed was
removed by filtration. Purification through a column
of Amberlite CG-50 (NH4 form) gave the titled com-
pound. Yield 560 mg (26%).
Elementary analysis:
Found: C 47.85, H 7.~5; N 15.40%
Calculated for C18H35Ns08:
C 48.11; H 7.80; N 15.59%
(7) Preparation of 3',41-dideoxykanamycin B
3'4'-Dideoxy-3'-eno-kanamycin B (120 mg) was
dissolved in water (4 ml), to which Raney nickel (0.2
ml) was added. Hydrogen was passed through the solution `
for 2 hours under atmospheric conditions of temperature
., . :
and pressure. After the catalys~ used was filte~red off,
the ~iltrate was concentrated to dryness. Yield 108 mg `
(95%).
,
;~ 20 Example 2
(l~ Preparation of penta-N-t-butoxycarbonyl-kanamycin B
- Xanamycin B~(lO g) was added to a mixture of
water (34 ml), triethylamine (24 ml) and dimethyl-
Pormamide (48 ml). Then~ t-butyl-S-(4,6-dimethyl- ~
pyrimidin-2-yl)-thiol-carbonate (40 g) was added to the
mixture at room temperature and the mixture was stirred
at that temperature for 18 hours. Addition of water
- (150 ml) to the mixture formed crystals which were re-
covered by filtration and washed thoroughly with an
aqueous saturated solution of ethyl acetate. Yield 20
- 35
. . .
~7~ii5~qE~ :
g (l00~). mp.229~~34C (decomposition with foaming).
Elementary analysis:
Found: C 52.61; H 7.86; N 6.93%
Calculated for C43H77NsO20:
C 52~47; H 7.90; N 7.12%
(2) Preparation of 3 t ~ 41-~-epoxy-penta-N~t-butoxy-
carbonyl-4",6"-O-cyclohexylidene-kanamycin B
Penta-N-t-butoxykanamycln B (10 g) was treated
in the same ways as those described in Example 1 (2),
(3) and (4) above, yielding the titled compound. Yield
80%, ~a~2D ~ 27(c=l.O, pyrldine). mp. 232_234C
(decomposition with foaming).
(3) Preparation of 3',4'-episulfido-penta-N-t-butoxy-
carbonyl-4",6"-O-cyclohexylidene-kanamycin B
3l~4'-~-Epoxy-penta-N-t-butoxyc~*x~yl-4~6~ ~ cyclo-
hexylidene-kanamycin B (10 g) was suspended in n butanol
'l00 ml), to which was added potassium n-butylxanthate ~-
(9 5 g) and the reaction was conducted at 90C for 2
hours. After the reaction was completed, the mixture
was cooled and washed twice with l00 ml portions of
water and the butanol layer separated was concentrated
to dryness, affording a mixture comprising 3',4'-
episulfido-penta-N-t-butoxycarbonyl-4",6~t-cyclohexylidene-
kanamycin B and 3',4'-dideoxy-31-eno-penta-N-t-butoxy-
carbonyl-4',6"-cyclohexylidene kanamycin B. Yield ll g.
The crude product was subjected to silica gel chromato-
graphy using chloroform-methanol (50:l by volume) as
developer, to isolate 31,4'-episulfido-penta-N-t-butoxy-
carbonyl-4",6"-cyclohexylidene-kanamycin B. Yield 3.9 g
(35%)- [~] D + 23 (c= l.0, pyridine). mp. 235~238C
- 36
(decomposition with foaming).
Elementary analysis:
Found: C 55.10; H 7.94; N 6.31; S 3.30%
Calculated for C~gH33NsOI8S:
C 55.39; H 7.89; N 6.59; S 3.02%
(4) Preparation of 3',4'-dideoxy-3'-eno-kanamycin B
3',4'-Episulfido-penta-N-t-butoxycarbonyl-4",
6"-0-cyclohexylidene-kanamycin B (1.15 g) was dissolved
in methanol (12 ml)g to which was added concentrated
... .
10 hydrochloric acid (3 ml) and the reaction was conducted
at room temperature for 3 hours.
The reaction mixture was concentrated to dryness
and the resulting residue was dissolved in water (18
ml) and the pH of the solution was a~usted to 6.5 by
the addition of lN sodium hydroxide solution (2.5 ml3.
The solution was passed through a column of 20 ml of
Amberlite CG-50 (N~4+ form). The adsorbed column was
washed with water and then O.lN aqueous ammonia and
subsequently eluated with 0.3N aqueous ammonia. The
concentration of the eluate gave the titled compound.
Yield 194 mg.
(5) Preparation o~f 3',4'-di~eoxykanamycin B
, .. . .
3'4'-Dideoxy-3'-eno-kanamycin B (120 mg) was
dissolved in water (4~ml), to which was added Raney
nickel (0.2 ml3 and hydrogen was passed through the
mixture for 2 hours under atmospheric temperatùre and
pressure ~conditions. After the catalyst was filtered
off, the filtrate was concentrated to dryness, giving
the tilted compound. Yield 108 mg (90%).
; 30 Example 3
* Trade ~Iark
- 37
7~ 6
Preparation of 3',4'-episulfido-penta-N-ethoxycarbonyl-
4",6"-O-cyclohexylidene-kanamycin B
3',4'-~-Epoxy-penta-N-ethoxycarbonyl-4", 6 ~-o-
~ cyclohexylidene-kanamycin B (100 mg) which was prepared
: by the method described in Example l of DT-OS 2,555,479
was dissolved in pyridine (5 ml), to which was added
potassium ethyl xanthate (100 mg) and the mixture was
refluxed for l.5 hours and then concentrated to dryness.
A mixture of water and chloroform (2:3 by volume) was
added to the solld residue and the chloroform layer
was separated, was~hed three times with 20 ml portions
of water and concentrated to dryness, yielding 70~mg
of a crude product comprising 3',4'-episulfido-penta-
N-ethoxycarbonyl-4",6"-O-cyclohexylidene-kanamycin B
and 3',4'-dideoxy-3'-eno-penta-N-ethoxycarbonyl-4",6"-
O-cyclohexylidene~-kanamycin B.
The isolation of the respective compounds was
carried out by thin layer chromatography ln the same
manner as that used in Example 1 (5) above.
; 20 Example 4
! (l) Preparation of 3',4l-dideoxy-3'-eno-penta-N-
~ ~ !
ethoxycarbonyl-4",6"-O-cyclohexylidene~-kanamycin B
3',4'-Episulfido-penta-N-ethoxycarbonyl-4" ,6~-o-
cyclohexylidene-kanamycin B (470 mg) which was prepared
as described in Example l (5)(or Example 3tl)) above
was dissolved in methanol (2 ml), to which was added
hydrazine hydrate (0.22 ml) and the mixture was allowed
to stand at room temperature for 2 hours. The reaction
mixture was then concentrated to dryness and treated
with water (20 ml) to form preclpitate which was re-
` - 38
covered by filtration. Yield 362 mg (80%). [~]D
24.7 (c=l.0, methanol).
Elementary analysis:
Found: C 52.31; H 7.53; N 7.49%
Calculated for C3sH6 sNsOI a:
C 52.50; H 7.36; N 7.85%
(2) Preparation of 3',4'-dideoxy-3'-eno-kanamycin B
3',4~-Dideoxy-3 r -eno-penta-N-Ethoxycarbonyl-4'i,
6"-cyclohexylidene-kanamycin B (475 mg) was dissolved
in methanol (5 ml) and treated in the same manner as
that described in Example 1 (6), affordlng the titled
compound.
; (3) Prepara~ion of 3',4'-dideoxykanamycin B
3',4'-Dideoxy-3i-eno-kanamycin B was treated
as similar as in Example 1 (7), affording the titled
compound.
Example 5
(1) Preparation of 3',4'-dideoxy-3'~-eno-penta-N-t-
butoxy-4",6"-0-cyclohexylidene-kanamycin B
3',4'-Episul~ido-penta-N-t-butoxycarbonyl-4",6"-
0-cyclohexylidene-kanamycin B (585 mg) which was prepared
as in Example 2 (3) was~dissolve~d in methanol (7 ml), to
which was added Raney nickel (R-100)(500 mg) and the
mixture was stirred at room temperature (20C) for 2
hours. After the Raney nickel was removed by filtration,
the filtrate was concentrated to dryness, affording the
titled compound. Yield 450 mg (80%).
(2) Preparation of 3',4'-dideoxykanamycin B
3',4'-Dideoxy-3'-eno-penta-N-t-butoxy-4",6"-
0-cyclohexylidene-kanamycin B (450 mg) was treated as
~ 39
.
5~
similar as in Example 1 (6) and (7), affording the titled
compound. Yield 90%.
Example 6
(1) Preparation of 3'~4'-~-epoxy-penta~N-t-butoxycarbonyl-
4",6" 0-cyclohexylidene-2"-0-benzoyl-kanamycin ~
3',4'-~-Epoxy-penta-N-t-butoxycarbony1-4",6"-0-
cyclohexylidene-kanamycin B (2.0 g) was dissolved in
dry pyridine (40 ml), to which was added benzoyl chloride
(0.8 ml) under ice-cooling and the mixture was allowed to
stand for reaction at 5C for 30 minutes. Then, water
(2 ml) was added to the reaction mixture and~the mlxture~
; was concentrated to give a syrup which was then poured
into water (20 ml) to form precipitate. The precipltate
was recovered by filtration and dried to yield the kitled
compound. Yield 2.16 g (98.3%).
`~ (2) Preparation o~ 4'-deoxy-4'-:iodo-penta-N-t-butoxy-
carbonyl-4",6"-0-cyclohexylidene--2"-0-benzoyl-kanamycin B
3',4'-~-epoxy-penta-N-t-butoxycarbonyl-4",6"-0-
cyclohexylidene-2"-0-benzoyl-kanamycin B (2.1 g) was
dissolved in acetone (60 ml), to which were added sodium~
od~de (1.4 g), sodium acetate (80 mg) and glacial acetic
acid~(1.4 ml) and the resulting mixture was refluxed~
for about 8 hours.
After the completion of the reaction, the mlxture
was cooled to deposit crystals which were recovered by
filtration. Yield 2.25 g (94%). mp. 171_176C (with
` decomposition).
Elementary analysis:
Found: C 52.81; H 7.11; N 5.31; I 10.39
Calculated for C~3H7 6 NsOlgI:
- 40
~ 6~ 6
C 52.62; H 6.94; N 5.48; I 9.93%
(3) Preparation of 3',4'-dideoxy-3'-eno-penta-N-t-butoXy-
carbonyl-4",6"-0-cyclohexylidene-2"-0-benzoyl-kanamycin B
4?-Deoxy-4'-iodo-penta-N-t-butoxycarbonyl-4",6"-
0-cyclohexylidene-2"-0-benzoyl-kanamycin B (452 mg) was
dissolved in dry pyridine (9 ml), to which was added
benæylsulfonyl chloride (305 mg) under cooling to 0~5C
for about 30 minutes.
After the completion of the reaction, methanol
(0.18 ml) was addéd to the reaction mixture which was
then heated to 90C for 50 minutes~ cooled to room tem-
perature. The mixture was concentrated to a syrup, to
which water (10 ml) was added to deposit crystals. The
; crystals were recovered by filtration and washed with
water to obkain the titled compound in the form of
a wet cake.
.
Identification of the compound thus obtained
was made by silica-gel thin layer chromatography using
carbon tetrachloride-acetone (4:1 by volume) as developer.
(4) Preparation of 3',4'-dideoxy-3'-eno-penta-N-t-
~ butoxycarbonyl-4",6"-0-cyclohexylidene-kanamycin B~
; The wet cake of the compound obtained in the
step (3) above was dissolved in methanol (20 ml), to
which sodium methyla~e was added to adjust the pH to
9.0~10.0 and the mixture was stirred at room temperature
for 30 minutes, neutralized with lN HCl and concentrated
to a syrup. Addition of water to the syrup formed a
precipitate which was recovered by filtration, washed
with water arld dried to a~ford the titled compound.
Yield 360 mg (100%).
_ 41
.
